| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 138,153 | 87,630 | 61,385 | 90,285 |
| Accounts receivable, net | 135,862 | 158,429 | 137,673 | 109,726 |
| Inventories, net | 222,098 | 206,465 | 196,667 | 191,464 |
| Prepaid expenses and other current assets | 15,060 | 7,458 | 6,930 | 8,088 |
| Assets held for sale | 0 | 6,530 | NaN | NaN |
| Total current assets | 511,173 | 466,512 | 402,655 | 399,563 |
| Property and equipment, gross | 105,005 | 103,405 | NaN | NaN |
| Less accumulated depreciation | 39,995 | 38,348 | NaN | NaN |
| Property and equipment, net | 65,010 | 65,057 | 69,509 | 57,501 |
| Intangible assets, net | 630 | 632 | 491 | 527 |
| Goodwill | 3,530 | 3,530 | 3,530 | 3,530 |
| Deferred tax assets, net | 69,969 | 73,261 | 74,433 | 79,235 |
| Right-of-use assets | 6,402 | 6,650 | 9,271 | 8,961 |
| Deposits and other assets | 8,470 | 8,600 | 8,798 | 9,063 |
| Total assets | 665,184 | 624,242 | 568,687 | 558,380 |
| Current portion of deferred revenue | NaN | NaN | NaN | 143 |
| Accounts payable | 20,523 | 22,519 | 24,021 | 29,769 |
| Accrued expenses and other current liabilities | 48,561 | 40,466 | 28,827 | 43,902 |
| Current portion of long-term debt | 3,281 | 2,813 | 2,344 | NaN |
| Current portion of lease obligations | 1,176 | 1,096 | 1,298 | 1,127 |
| Liabilities held for sale | 0 | 2,647 | NaN | NaN |
| Total current liabilities | 73,541 | 69,541 | 56,490 | 74,941 |
| Long-term debt | 193,584 | 69,330 | 70,084 | NaN |
| Senior notes payable, net of discount | NaN | NaN | NaN | 73,397 |
| Deferred revenue, net of current portion | 1,369 | 1,405 | 1,440 | 1,476 |
| Other non-current liabilities | NaN | 0 | 90 | 2 |
| End of term fee | NaN | 0 | NaN | 938 |
| Lease obligations, net of current portion | 6,365 | 6,646 | 9,397 | 9,301 |
| Total liabilities | 274,859 | 146,922 | 137,501 | 160,055 |
| Common stock - voting, 0.0001 par value, 300,000,000 shares authorized, march 31, 2026 240,962,203 issued and 232,288,977 outstanding december 31, 2025 239,793,566 issued and 237,874,496 outstanding | 24 | 24 | 24 | 24 |
| Treasury stock, at cost, 8,673,226 and 1,919,070 shares as of march 31, 2026 and december 31, 2025, respectively | 143,170 | 32,090 | 23,188 | 15,148 |
| Additional paid-in capital | 649,796 | 671,039 | 665,382 | 660,909 |
| Accumulated deficit | -116,325 | -161,653 | -211,032 | -247,460 |
| Total stockholders equity | 390,325 | 477,320 | 431,186 | 398,325 |
| Total liabilities and stockholders equity | 665,184 | 624,242 | 568,687 | 558,380 |
ADMA BIOLOGICS, INC. (ADMA)
ADMA BIOLOGICS, INC. (ADMA)